Compare BDL & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDL | MDAI |
|---|---|---|
| Founded | 1959 | 2013 |
| Country | United States | United States |
| Employees | 1990 | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.2M | 55.9M |
| IPO Year | N/A | N/A |
| Metric | BDL | MDAI |
|---|---|---|
| Price | $31.05 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.25 |
| AVG Volume (30 Days) | 616.0 | ★ 340.2K |
| Earning Date | 12-26-2025 | 11-11-2025 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | ★ 41.91 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $201,851,000.00 | $23,168,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.31 | ★ N/A |
| Revenue Growth | ★ 8.84 | N/A |
| 52 Week Low | $22.61 | $1.04 |
| 52 Week High | $35.98 | $3.25 |
| Indicator | BDL | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 39.60 |
| Support Level | $28.61 | $1.63 |
| Resistance Level | $30.01 | $1.76 |
| Average True Range (ATR) | 0.42 | 0.10 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 66.92 | 9.43 |
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.